Premature Puberty and Thimerosal-Containing Hepatitis B Vaccination: A Case-Control Study in the Vaccine Safety Datalink

Studies suggest a relationship between exposure to endocrine disrupters, such as mercury (Hg), and premature puberty. Hg exposure from Thimerosal-containing hepatitis B vaccine, administered at specific intervals within the first six months of life, and the child’s long-term risk of being...

Full description

Bibliographic Details
Main Authors: David A. Geier, Janet K. Kern, Mark R. Geier
Format: Article
Language:English
Published: MDPI AG 2018-11-01
Series:Toxics
Subjects:
Online Access:https://www.mdpi.com/2305-6304/6/4/67
_version_ 1811240901352095744
author David A. Geier
Janet K. Kern
Mark R. Geier
author_facet David A. Geier
Janet K. Kern
Mark R. Geier
author_sort David A. Geier
collection DOAJ
description Studies suggest a relationship between exposure to endocrine disrupters, such as mercury (Hg), and premature puberty. Hg exposure from Thimerosal-containing hepatitis B vaccine, administered at specific intervals within the first six months of life, and the child’s long-term risk of being diagnosed with premature puberty (ICD-9 code: 259.1), was retrospectively examined, using a hypothesis-testing, longitudinal case-control design on prospectively collected data, in the Vaccine Safety Datalink (VSD). Cases diagnosed with premature puberty were significantly more likely to have received increased exposure to Hg from hepatitis B vaccines preserved with Thimerosal given in the first month after birth (odds ratio (OR) = 1.803), first two months after birth (OR = 1.768), and first six months after birth (OR = 2.0955), compared to control subjects. When the data were separated by gender, the effects remained among females but not males. Female cases, as compared to female controls, were significantly more likely in a dose-dependent manner to have received a greater exposure to Hg from hepatitis B vaccines preserved with Thimerosal, given in the first six months after birth (OR = 1.0281 per µg Hg). The results of this study show a dose-dependent association between increasing organic Hg exposure from Thimerosal-containing hepatitis B vaccines administered within the first six months of life and the long-term risk of the child being diagnosed with premature puberty.
first_indexed 2024-04-12T13:27:48Z
format Article
id doaj.art-ed270be3a199408b8817a663e3c7c772
institution Directory Open Access Journal
issn 2305-6304
language English
last_indexed 2024-04-12T13:27:48Z
publishDate 2018-11-01
publisher MDPI AG
record_format Article
series Toxics
spelling doaj.art-ed270be3a199408b8817a663e3c7c7722022-12-22T03:31:16ZengMDPI AGToxics2305-63042018-11-01646710.3390/toxics6040067toxics6040067Premature Puberty and Thimerosal-Containing Hepatitis B Vaccination: A Case-Control Study in the Vaccine Safety DatalinkDavid A. Geier0Janet K. Kern1Mark R. Geier2Institute of Chronic Illnesses, Inc., 14 Redgate Court, Silver Spring, MD 20905, USAInstitute of Chronic Illnesses, Inc., 14 Redgate Court, Silver Spring, MD 20905, USAInstitute of Chronic Illnesses, Inc., 14 Redgate Court, Silver Spring, MD 20905, USAStudies suggest a relationship between exposure to endocrine disrupters, such as mercury (Hg), and premature puberty. Hg exposure from Thimerosal-containing hepatitis B vaccine, administered at specific intervals within the first six months of life, and the child’s long-term risk of being diagnosed with premature puberty (ICD-9 code: 259.1), was retrospectively examined, using a hypothesis-testing, longitudinal case-control design on prospectively collected data, in the Vaccine Safety Datalink (VSD). Cases diagnosed with premature puberty were significantly more likely to have received increased exposure to Hg from hepatitis B vaccines preserved with Thimerosal given in the first month after birth (odds ratio (OR) = 1.803), first two months after birth (OR = 1.768), and first six months after birth (OR = 2.0955), compared to control subjects. When the data were separated by gender, the effects remained among females but not males. Female cases, as compared to female controls, were significantly more likely in a dose-dependent manner to have received a greater exposure to Hg from hepatitis B vaccines preserved with Thimerosal, given in the first six months after birth (OR = 1.0281 per µg Hg). The results of this study show a dose-dependent association between increasing organic Hg exposure from Thimerosal-containing hepatitis B vaccines administered within the first six months of life and the long-term risk of the child being diagnosed with premature puberty.https://www.mdpi.com/2305-6304/6/4/67ethylmercurymercurymerthiolatepremature pubertythiomersal
spellingShingle David A. Geier
Janet K. Kern
Mark R. Geier
Premature Puberty and Thimerosal-Containing Hepatitis B Vaccination: A Case-Control Study in the Vaccine Safety Datalink
Toxics
ethylmercury
mercury
merthiolate
premature puberty
thiomersal
title Premature Puberty and Thimerosal-Containing Hepatitis B Vaccination: A Case-Control Study in the Vaccine Safety Datalink
title_full Premature Puberty and Thimerosal-Containing Hepatitis B Vaccination: A Case-Control Study in the Vaccine Safety Datalink
title_fullStr Premature Puberty and Thimerosal-Containing Hepatitis B Vaccination: A Case-Control Study in the Vaccine Safety Datalink
title_full_unstemmed Premature Puberty and Thimerosal-Containing Hepatitis B Vaccination: A Case-Control Study in the Vaccine Safety Datalink
title_short Premature Puberty and Thimerosal-Containing Hepatitis B Vaccination: A Case-Control Study in the Vaccine Safety Datalink
title_sort premature puberty and thimerosal containing hepatitis b vaccination a case control study in the vaccine safety datalink
topic ethylmercury
mercury
merthiolate
premature puberty
thiomersal
url https://www.mdpi.com/2305-6304/6/4/67
work_keys_str_mv AT davidageier prematurepubertyandthimerosalcontaininghepatitisbvaccinationacasecontrolstudyinthevaccinesafetydatalink
AT janetkkern prematurepubertyandthimerosalcontaininghepatitisbvaccinationacasecontrolstudyinthevaccinesafetydatalink
AT markrgeier prematurepubertyandthimerosalcontaininghepatitisbvaccinationacasecontrolstudyinthevaccinesafetydatalink